Second-line Afatinib vs Erlotinib for Advanced Lung Squamous Cell Carcinoma: Final Analysis of the Phase 3 LUX-Lung 8 Trial
No Thumbnail Available
Identifiers
Date
2019-11-01
Authors
Goss, G. D.
Cobo, M.
Lu, S.
Syrigos, K.
Lee, K. H.
Goker, E.
Georgoulias, V.
Li, W.
Isla, D.
Morabito, A.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier science inc
Metrics
Export
Abstract
Description
MeSH Terms
DeCS Terms
CIE Terms
Keywords
lung SCC, afatinib, erlotinib, second-line